Data Presentation: Reata Announces Improvements in Kidney Function with Bardoxolone Methyl Maintained for Two Years in PAH Patients from LARIAT Trial

Reata announced results from the long-term follow up portion of the LARIAT study demonstrating that pulmonary arterial hypertension patients treated with bardoxolone methyl experienced kidney function improvements that were durable for two years and not associated with adverse outcomes.